Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00252239|
Recruitment Status : Terminated (Slow enrollment)
First Posted : November 11, 2005
Results First Posted : January 19, 2015
Last Update Posted : March 17, 2015
|Condition or disease||Intervention/treatment||Phase|
|Stroke||Drug: tenecteplase Drug: tissue plasminogen activator, tPA||Phase 2|
Stroke is the third leading cause of death and a leading cause of adult disability in the United States and worldwide. To date, the only scientifically-proven and FDA-approved treatment for acute stroke is the clot-busting drug, tissue plasminogen activator (tPA). A newer clot-busting drug, tenecteplase (TNK), has chemical properties that make it a potentially safer and more effective drug for treating stroke. Preliminary testing of TNK in patients with acute stroke has been encouraging enough to warrant further testing.
This study, TNK-S2B, will compare three different doses of TNK with standard tPA treatment in patients with acute stroke. Patients will be chosen randomly to receive either TNK or tPA. Neither the patient nor his/her doctor will know which medication the patient received until the study is completely finished.
The first part of the study will look at results of treatment in the first 24 hours to select the best dose of TNK to carry forward into a more detailed comparison with standard tPA treatment. After at least 100-150 pairs of the best dose of TNK and tPA patients have been enrolled, entry into the study will pause, and the outcomes at 3 months after stroke will be compared to see if the results of TNK treatment are sufficiently promising as an improvement over standard treatment to justify expanding the study to find a definitive answer.
The study, which will be conducted in at least 8 large medical centers, is expected to last about 3 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||112 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Phase 2B Study of Tenecteplase (TNK) in Acute Ischemic Stroke (TNK-S2B)|
|Study Start Date :||November 2005|
|Primary Completion Date :||March 2009|
|Study Completion Date :||September 2009|
Active Comparator: 1
This study will compare 3 different doses of tenecteplase to tPA.
Other Name: TNK
Active Comparator: 2
tissue plasminogen activator, tPA
Drug: tissue plasminogen activator, tPA
To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
Other Name: tPA
- Functional Handicap (Modified Rankin Score) [ Time Frame: 3 months ]The scale range is from 0 (perfect health without symptoms) to 6 (death). Percentage of participants with Modified Rankin Score >=4 are reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00252239
|United States, California|
|University of California at San Diego|
|San Diego, California, United States, 92103-8466|
|United States, Colorado|
|Colorado Neurological Institutes|
|Englewood, Colorado, United States, 80113-2771|
|United States, Maryland|
|Johns Hopkins-Bayview Medical Center|
|Baltimore, Maryland, United States, 21224|
|United States, Michigan|
|University of Michigan|
|Ann Arbor, Michigan, United States, 48109-0316|
|United States, New York|
|Long Island Jewish Hospital|
|New Hyde Park, New York, United States, 11040|
|Mount Sinai Medical Center|
|New York, New York, United States, 10029|
|Columbia University, Statistical Analysis Center|
|New York, New York, United States, 10032|
|United States, Texas|
|University of Texas at Houston|
|Houston, Texas, United States, 77030|
|United States, Virginia|
|University of Virginia Health System|
|Charlottesville, Virginia, United States, 22908|
|Principal Investigator:||E. Clarke Haley, Jr., M.D.||Clinical Coordinating Center, Department of Neurology, University of Virginia Health System|
|Principal Investigator:||John L. P. Thompson, Ph.D.||Statistical Analysis Center, Department of Biostatistics, Mailman School of Public Health|